All In Biotech

Drug Trial Radar · NCT07263438

Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 Trial

Open-label Phase II Clinical Trial to Test the Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

59

Planned (sponsor's estimate)

Start

Nov 3, 2025

Primary completion

Mar 30, 2028

Study completion Dec 31, 2030

Sponsor

Lead sponsor
Centre Hospitalier Universitaire VaudoisAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 4, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicentric phase II open-label clinical trial aiming to assess the efficacy of the combination of trimipramine and atezolizumab with bevacizumab in patients with recurrent glioblastoma. Eligible patients will be assigned to two cohorts depending on whether there is a medical indication for a neurosurgical resection from first recurrent tumor or not. The aim of the cohort 1 (patients without indication for surgery) is to analyze the clinical efficacy of this triple combination in recurrent glioblastoma. 48 patients will be registered. The aim of cohort 2 (patients with indication for surgery) is to confirm the level of trimipramine that can be achieved in the tumor tissue and cerebrospinal fluid collected during surgery. At least 5 patients will be registered. All patients will receive the combination treatment (trimipramine and atezolizumab associated with bevacizumab) for a maximum period of 2 years from registration. The treatment schedule is slightly different for the 2 cohorts because of the neurosurgical resection foreseen for cohort 2 and the requirement to start bevacizumab only after the surgery. After the end of treatment, all patients will be followed up for safety during 90 days from first treatment administration and then up to 3 years from registration.

Conditions

  • Glioblastoma
  • Recurrence Tumor

Interventions

  • TrimipramineDrug

    Trimipramine: daily oral intake at 75mg/ day for 7 days, then at 150 mg/ day

  • Cohort 1: AtezolizumabBiological

    Atezolizumab: intravenous administration at 1200 mg on the first day of 3-week cycles.

  • BevacizumabBiological

    Bevacizumab will be administered intravenously at 15 mg/kg on the first day of 3-week cycles.

  • Cohort 2: AtezolizumabBiological

    Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on the first day of 3-week cycles. Administration will occur once, then will be interrupted during a recovery period of 14-days post surgery, and then resumed.

  • Cohort 2: BevacizumabBiological

    Bevacizumab will be administered intravenously at 15 mg/kg on the first day of 3-week cycles. The first administration will take place 5 weeks after surgery.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohort 1: Progression-free survival rate [PFSR]Time frame: 6 months after last patient's registration
  2. Cohort 2: Level of trimipramine in the tumor tissue and cerebrospinal fluid [CSF]Time frame: 3 months after last patient's surgery

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Universitätsspital Basel

    Basel, Basel, Switzerland · Recruiting

  • Kantonsspital Aarau

    Aarau, Canton of Aargau, Switzerland · Recruiting

  • Bern Inselspital

    Bern, Canton of Bern, Switzerland · Recruiting

  • HFR Fribourg - Hôpital cantonal

    Fribourg, Canton of Fribourg, Switzerland · Recruiting

  • Luzerner Kantonsspital

    Lucerne, Canton of Lucerne, Switzerland · Recruiting

  • Centre Hospitalier Universitaire Vaudois

    Lausanne, Canton of Vaud, Switzerland · Recruiting

  • Universitätsspital Zürich

    Zurich, Canton of Zurich, Switzerland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.